Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Catalyst Pharm Inc (CPRX)

Catalyst Pharm Inc (CPRX)
21.78 -0.96 (-4.22%) 14:13 ET [NASDAQ]
21.71 x 100 21.79 x 11
Realtime by (Cboe BZX)
21.71 x 100 21.79 x 11
Realtime 21.91 -0.83 (-3.67%) 09:18 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
20.66
Day High
22.29
Open 22.11
Previous Close 22.74 22.74
Volume 768,106 768,106
Avg Vol 1,681,351 1,681,351
Stochastic %K 21.92% 21.92%
Weighted Alpha +31.40 +31.40
5-Day Change -2.71 (-11.24%) -2.71 (-11.24%)
52-Week Range 14.47 - 26.16 14.47 - 26.16
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,761,773
  • Shares Outstanding, K 121,450
  • Annual Sales, $ 491,730 K
  • Annual Income, $ 163,890 K
  • EBIT $ 233 M
  • EBITDA $ 270 M
  • 60-Month Beta 0.79
  • Price/Sales 5.29
  • Price/Cash Flow 8.75
  • Price/Book 3.51

Options Overview Details

View History
  • Implied Volatility 81.50% ( +33.35%)
  • Historical Volatility 51.46%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 81.50% on 04/10/25
  • IV Low 19.27% on 06/17/24
  • Put/Call Vol Ratio 3.37
  • Today's Volume 262
  • Volume Avg (30-Day) 266
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 3,931
  • Open Int (30-Day) 3,828

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.51
  • Number of Estimates 3
  • High Estimate 0.57
  • Low Estimate 0.47
  • Prior Year 0.31
  • Growth Rate Est. (year over year) +64.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.23 +5.78%
on 03/11/25
Period Open: 20.67
26.16 -18.19%
on 03/24/25
+0.73 (+3.53%)
since 03/10/25
3-Month
20.23 +5.78%
on 03/11/25
Period Open: 21.92
26.16 -18.19%
on 03/24/25
-0.52 (-2.37%)
since 01/10/25
52-Week
14.47 +47.89%
on 05/09/24
Period Open: 15.88
26.16 -18.19%
on 03/24/25
+5.52 (+34.76%)
since 04/10/24

Most Recent Stories

More News
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday

As predicted by many analysts, economists, and investors, the sweeping tariffs announced by the Trump administration on Wednesday decimated the stock market on Thursday. It had one of its worst trading...

AZN : 64.82 (-2.91%)
$SPX : 5,266.20 (-3.49%)
VEEV : 210.33 (-3.09%)
CPRX : 21.78 (-4.22%)
AMGN : 278.53 (-4.31%)
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference

CPRX : 21.78 (-4.22%)
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today

The drugmaker confirmed there's a strong market for two of its treatments.

CPRX : 21.78 (-4.22%)
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

CPRX : 21.78 (-4.22%)
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

CPRX : 21.78 (-4.22%)
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies

CPRX : 21.78 (-4.22%)
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

CPRX : 21.78 (-4.22%)
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

CPRX : 21.78 (-4.22%)
Catalyst Pharmaceuticals CEO Richard J. Daly to Present at 43rd Annual J.P. Morgan Healthcare Conference

Richard J. Daly, CEO of Catalyst Pharmaceuticals, will present at the J.P. Morgan Healthcare Conference on January 16, 2025.Quiver AI SummaryCatalyst Pharmaceuticals, Inc. announced that Richard J. Daly,...

CPRX : 21.78 (-4.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights...

See More

Key Turning Points

3rd Resistance Point 26.41
2nd Resistance Point 24.74
1st Resistance Point 23.74
Last Price 21.78
1st Support Level 21.07
2nd Support Level 19.40
3rd Support Level 18.40

See More

52-Week High 26.16
Last Price 21.78
Fibonacci 61.8% 21.69
Fibonacci 50% 20.31
Fibonacci 38.2% 18.93
52-Week Low 14.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar